# US 2003/0083256 A1 · Compositions and methods for enhancing drug delivery across and into epithelial tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083256 A1
- Document ID: US20030083256A1
- Status: Published application
- Kind: A1
- Application number: 10/209,421
- Filed: 2002-07-30
- Published: 2003-05-01
- Earliest claimed: 1999-08-24
- Assignees: Cellgate, Inc.
- Inventors: Jonathan B. Rothbard; Paul A. Wender; P. Leo McGrane; Lalitha V.S. Sista; Thorsten A. Kirschberg
- Web page: https://patentgrep.com/patent/US20030083256A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/557: {the modifying agent being biotin}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/665: {the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/085: {conjugated systems}
- A61K 49/146: {the peptide being a polyamino acid, e.g. poly-lysine}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

## Claims

### Claim 1

A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial or endothelial tissue, the method comprising:
contacting the epithelial tissue with a conjugate that comprises the compound and a delivery-enhancing transporter,
wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter.

### Claim 2 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter comprises a non-peptide backbone.

### Claim 3 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter is not attached to an amino acid sequence to which the delivery enhancing transporter molecule is attached in a naturally occurring protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter comprises from 5 to 25 guanidino or amidino moieties.

### Claim 5 (depends on 4)

The method of claim 4, wherein the delivery-enhancing transporter comprises between 7 and 15 guanidino moieties.

### Claim 6 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter comprises at least 6 contiguous guanidino and/or amidino moieties.

### Claim 7 (depends on 1)

The method of claim 1, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the delivery-enhancing transporter comprises 5 to 25 arginine residues or analogs thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein at least one arginine is a D-arginine.

### Claim 10 (depends on 9)

The method of claim 9, wherein all of the arginines are D-arginines.

### Claim 11 (depends on 7)

The method of claim 7, wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs.

### Claim 12 (depends on 7)

The method of claim 7, wherein the delivery-enhancing transporter comprises at least 5 contiguous arginines or arginine analogs.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound is attached to the delivery enhancing transporter by a linker.

### Claim 14 (depends on 13)

The method of claim 13, wherein the linker is a releasable linker which releases the compound from the delivery-enhancing transporter after the compound has passed into and through one or more layers of an epithelial or endothelial tissue.

### Claim 15 (depends on 14)

The method of claim 14, wherein the compound is biologically active upon release from the linker.

### Claim 16 (depends on 1)

The method of claim 1, wherein the compound is substantially inactive when conjugated to the delivery-enhancing transporter.

### Claim 17 (depends on 14)

The method of claim 14, wherein the half-life of the conjugate is between 5 minutes and 24 hours upon contact with the epithelial or endothelial tissue.

### Claim 18 (depends on 17)

The method of claim 17, wherein half-life of the conjugate is between 30 minutes and 2 hours upon contact with the epithelial or endothelial tissue.

### Claim 19 (depends on 14)

The method of claim 14, wherein the compound is released from the linker by solvent-mediated cleavage.

### Claim 20 (depends on 13)

The method of claim 13, wherein the conjugate is substantially stable at acidic pH but the compound is substantially released from the delivery-enhancing transporter at physiological pH.

### Claim 21 (depends on 13)

The method of claim 13, wherein the conjugate has a structure selected from the group consisting of structures 3, 4, or 5, as follows:
10
wherein:
R1—X comprises the compound;
X is a functional group on the compound to which the linker is attached;
Y is N or C;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is substituted or unsubstituted S, O, N or C;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10.

### Claim 22 (depends on 21)

The method of claim 21, wherein X is selected from the group consisting of N, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.

### Claim 23 (depends on 21)

The method of claim 21, wherein the conjugate comprises structure 3 and R2 is selected to obtain a conjugate half-life of between 5 minutes and 24 hours.

### Claim 24 (depends on 23)

The method of claim 23, wherein R2 is selected to obtain a conjugate half-life of between 5 minutes and 24 hours.

### Claim 25 (depends on 21)

The method of claim 21, wherein the conjugate comprises structure 3, Y is N, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.

### Claim 26 (depends on 25)

The method of claim 25, wherein R2 is benzyl; k, m, and n are each 1, and X is O.

### Claim 27 (depends on 21)

The method of claim 21, wherein the conjugate comprises structure 4; R4 is S; R5 is NHR6; and R6 is hydrogen, methyl, allyl, butyl or phenyl.

### Claim 28 (depends on 21)

The method of claim 21, wherein the conjugate comprises structure 4; R5 is NHR6; R6 is hydrogen, methyl, allyl, butyl or phenyl; and k and m are each 1.

### Claim 29 (depends on 20)

The method of claim 20, wherein the conjugate comprises structure 6 as follows:
11
wherein:
R1—X comprises the compound;
X is a functional group on the compound to which the linker is attached;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
R3 comprises the delivery-enhancing transporter;
R4 is substituted or unsubstituted S, O, N or C;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl; and
k and m are each independently selected from 1 and 2.

### Claim 30 (depends on 29)

The method of claim 29, wherein X is selected from the group consisting of N, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.

### Claim 31 (depends on 29)

The method of claim 29, wherein R4 is S; R5 is NHR6; and R6 is hydrogen, methyl, allyl, butyl or phenyl.

### Claim 32 (depends on 1)

The method of claim 1, wherein the conjugate comprises at least two delivery-enhancing transporters.

### Claim 33 (depends on 1)

The method of claim 1, wherein the rate of delivery of the compound into and across the intact epithelial or endothelial tissue layer or layers is increased.

### Claim 34 (depends on 1)

The method of claim 1, wherein the amount of compound delivered into and across the intact epithelial or endothelial tissue layer or layers is increased.

### Claim 35 (depends on 1)

The method of claim 1, wherein delivery of the compound into and across the intact epithelial or endothelial tissue layers is significantly greater than that of the compound conjugated to the basic HIV tat peptide consisting of residues 49-57.

### Claim 36 (depends on 35)

The method of claim 35, wherein delivery of the compound into and across the intact epithelial tissue layers is at least two-fold greater than that of the compound conjugated to the basic HIV tat peptide consisting of residues 49-57.

### Claim 37 (depends on 36)

The method of claim 36, wherein delivery of the conjugate into and across the intact epithelial tissue layers is at least six-fold greater than that of the compound conjugated to the basic HIV tat peptide consisting of residues 49-57.

### Claim 38 (depends on 1)

The method of claim 1, wherein the compound is a diagnostic imaging or contrast agent

### Claim 39 (depends on 1)

The method of claim 1, wherein the compound is a non-nucleic acid.

### Claim 40 (depends on 1)

The method of claim 1, wherein the compound is a non-polypeptide.

### Claim 41 (depends on 1)

The method of claim 1, wherein the compound exerts its biological effect while or after passing into both the epidermis and the dermis.

### Claim 42 (depends on 41)

The method of claim 41, wherein the compound acts upon immune cells present in the dermis.

### Claim 43 (depends on 1)

The method of claim 1, wherein the compound is a therapeutic for skin disorders or a cosmetic.

### Claim 44 (depends on 43)

The method of claim 43, wherein the compound is selected from the group consisting of antibacterials, antifungals, antivirals, antiproliferatives, immunosuppressives, vitamins, analgesics, and hormones.

### Claim 45 (depends on 1)

The method of claim 1, wherein the epithelial tissue comprises a blood vessel and the compound enters the blood vessel from the epithelial tissue.

### Claim 46 (depends on 45)

The method of claim 45, wherein the compound exerts its biological effect after entry into the capillary system.

### Claim 47 (depends on 45)

The method of claim 45, wherein the compound is a systemically active agent.

### Claim 48 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of antibacterials, antifungals, antivirals, antiproliferatives, hormones, antiinflammatories, vitamins, and analgesics.

### Claim 49 (depends on 48)

The method of claim 48, wherein the compound is an antiinflammatory agent.

### Claim 50 (depends on 49)

The method of claim 49, wherein the compound is selected from the group consisting of corticosteroids, NSIADs, cromolyn, and nedocromil.

### Claim 51 (depends on 48)

The method of claim 48, wherein the compound is an antifungal agent.

### Claim 52 (depends on 51)

The method of claim 51, wherein the antifungal agent is an azole compound.

### Claim 53 (depends on 52)

The method of claim 52, wherein the azole compound is selected from the group comprising itraconazole, myconazole and fluconazole.

### Claim 54 (depends on 1)

The method of claim 1, wherein the compound is selected from the group comprising caffeine, proline, salicylic acid and vitamin E.

### Claim 55 (depends on 1)

The method of claim 1, wherein the compound is a therapeutic agent.

### Claim 56 (depends on 55)

The method of claim 55, wherein the therapeutic agent is selected from the group consisting of cyclosporin, insulin, a vasopressin, a leucine enkephalin, Asu-eel calcitonin, 5-fluorouracil, a salicylamide, a β-lactone, an ampicillin, a penicillin, a cephalosporin, a β-lactamase inhibitor, a quinolone, a tetracycline, a macrolide, a gentamicin, acyclovir, ganciclovir, a trifluoropyridine, and pentamidine.

### Claim 57 (depends on 1)

The method of claim 1, wherein the epithelial tissue is skin.

### Claim 58 (depends on 57)

The method of claim 57, wherein the conjugate is applied to intact skin.

### Claim 59 (depends on 57)

The method of claim 57, wherein the compound is delivered into and across one or more of the stratum corneum, stratum granulosum, stratum lucidum and stratum germinativum.

### Claim 60 (depends on 57)

The method of claim 57, wherein the compound crosses the stratum corneum in the absence of skin pretreatment.

### Claim 61 (depends on 57)

The method of claim 57, wherein the conjugate is administered topically and the compound is taken up by cells that comprise the follicular or interfollicular epidermis.

### Claim 62 (depends on 57)

The method of claim 57, wherein the conjugate is administered by a transdermal patch.

### Claim 63 (depends on 57)

The method of claim 57, wherein the conjugate is administered topically and the compound crosses into and across one or both of the papillary dermis and the reticular dermis.

### Claim 64 (depends on 63)

The method of claim 63, wherein the compound is taken up by cells present in the dermis.

### Claim 65 (depends on 64)

The method of claim 64, wherein the compound is taken up by one or more cells selected from the group consisting of fibroblasts, epithelial cells and immune cells.

### Claim 66 (depends on 1)

The method of claim 1, wherein the epithelial tissue comprises a mucous membrane.

### Claim 67 (depends on 66)

The method of claim 66, wherein the conjugate is administered by an oral, nasal, pulmonary, buccal, rectal, transdermal, vaginal or ocular route.

### Claim 68 (depends on 66)

The method of claim 66, wherein the compound is a systemically active agent.

### Claim 69 (depends on 68)

The method of claim 68, wherein the compound is selected from the group consisting of antibacterials, antifungals, antivirals, antiproliferatives, hormones, antiinflammatories, vitamins, and analgesics.

### Claim 70 (depends on 1)

The method of claim 1, wherein the epithelial tissue is gastrointestinal epithelium.

### Claim 71 (depends on 70)

The method of claim 70, wherein the compound acts in the gastrointestinal epithelium.

### Claim 72 (depends on 70)

The method of claim 70, wherein the compound is a therapeutic for a condition selected from the group consisting of Crohn's disease, ulcerative colitis, gastrointestinal ulcers, Crohn's disease, peptic ulcer disease, and abnormal proliferative diseases.

### Claim 73 (depends on 72)

The method of claim 72, wherein the compound is a therapeutic for ulcers and is selected from the group consisting of an H2 histamine inhibitor, an inhibitor of the proton-potassium ATPase, and an antibiotic directed at Helicobacter pylori.

### Claim 74 (depends on 1)

The method of claim 1, wherein the epithelial tissue is bronchial epithelium.

### Claim 75 (depends on 74)

The method of claim 74, wherein the compound is a therapeutic agent for treating a bronchial condition selected from the group consisting of cystic fibrosis, asthma, allergic rhinitis, and chronic obstructive pulmonary disease.

### Claim 76 (depends on 75)

The method of claim 75, wherein the condition is asthma and the therapeutic agent is selected from the group consisting of an antiinflammatory agent, a bronchodialator, and an immunosuppressive drug.

### Claim 77 (depends on 75)

The method of claim 75, wherein the therapeutic agent is an antiinflammatory agent selected from the group consisting of a corticosteroid, cromolyn, and nedocromil.

### Claim 78 (depends on 74)

The method of claim 74, wherein the conjugate is delivered by inhalation.

### Claim 79 (depends on 1)

The method of claim 1, wherein the endothelial tissue is a blood brain barrier.

### Claim 80 (depends on 79)

The method of claim 79, wherein the compound is a therapeutic for treating ischemia, Parkinson's disease, schizophrenia, cancer, acquired immune deficiency syndrome (AIDS), infections of the central nervous system, epilepsy, multiple sclerosis, neurodegenerative disease, trauma, depression, Alzheimer's disease, migraine, pain, and a seizure disorder.

### Claim 81

A conjugate that comprises a) a compound to be delivered into and across one or more layers of an animal epithelial or endothelial tissue, and b) a delivery-enhancing transporter that comprises 5 to 25 arginine residues; and c) a releasable linker which releases the compound, in biologically active form, from the delivery-enhancing transporter after the glucocorticoid or ascomycin has passed into and across one or more layers of the epithelial or endothelial tissue.

### Claim 82 (depends on 81)

The conjugate of claim 81, wherein the delivery-enhancing transporter comprises 7 to 15 arginine residues or arginine analogs.

### Claim 83 (depends on 81)

The conjugate of claim 81, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or arginine analogs.

### Claim 84 (depends on 81)

The conjugate of claim 81, wherein the delivery-enhancing transporter comprises at least 5 contiguous arginines or arginine analogs.

### Claim 85 (depends on 81)

The conjugate of claim 81, wherein the half-life of the conjugate is between 5 minutes and 24 hours upon contact with the epithelial or endothelial membrane.

### Claim 86 (depends on 81)

The conjugate of claim 81, wherein the compound is released from the linker by solvent-mediated cleavage.

### Claim 87 (depends on 81)

The conjugate of claim 81, wherein the conjugate is substantially stable at acidic pH but the compound is substantially released from the delivery-enhancing transporter at physiological pH.

### Claim 88 (depends on 81)

The conjugate of claim 81, wherein the conjugate is selected from the group consisting of structures 3, 4, or 5, as follows:
12
wherein:
R1—X comprises the compound;
X is a functional group on the compound to which the linker is attached;
Y is N or C;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is substituted or unsubstituted S, O, N or C;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10.

### Claim 89 (depends on 88)

The conjugate of claim 88, wherein X is selected from the group consisting of N, O, S, and CR7R8 wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.

### Claim 90 (depends on 88)

The conjugate of claim 88 wherein the conjugate comprises structure 3, Y is N, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.

### Claim 91 (depends on 90)

The conjugate of claim 90, wherein R2 is phenyl; k, m, and n are each 1, and X is O.

### Claim 92 (depends on 88)

The conjugate of claim 88, wherein the linker comprises structure 4; R4 is S; R5 is NHR6; and R6 is hydrogen, methyl, allyl, butyl or phenyl.

### Claim 93 (depends on 88)

The conjugate of claim 88, wherein the conjugate comprises structure 4; R5 is NHR6; R6 is hydrogen, methyl, allyl, butyl or phenyl; and k and m are each 1.

### Claim 94 (depends on 88)

The conjugate of claim 88, wherein the conjugate comprises:
13
wherein Ph is phenyl.

### Claim 95 (depends on 86)

The conjugate of claim 86, wherein the conjugate comprises structure 6 as follows:
14
wherein:
R1—X comprises the compound;
X is a functional group on the compound to which the linker is attached;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
R3 comprises the delivery-enhancing transporter;
R4 is substituted or unsubstituted S, O, N or C;
R5is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl; and
k and m are each independently selected from 1 and 2.

### Claim 96 (depends on 95)

The conjugate of claim 95, wherein X is selected from the group consisting of N, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.

### Claim 97 (depends on 95)

The conjugate of claim 95, where R4 is S; R5 is NHR6; and R6 is hydrogen, methyl, allyl, butyl or phenyl.

### Claim 98 (depends on 95)

The conjugate of claim 95, wherein the conjugate comprises:
15

### Claim 99

A transdermal drug formulation comprising:
a therapeutically effective amount of a therapeutic agent;
a delivery-enhancing polymer that comprises sufficient guanidino or amidino sidechain moieties to increase delivery of the conjugate across one or more layers of an animal epithelial tissue compared to the trans-epithelial tissue delivery of the biologically active agent in non-conjugated form; and
a vehicle suited to transdermal drug administration.

### Claim 100 (depends on 99)

The formulation of claim 99, wherein the formulation is in a topical dosage form.

### Claim 101 (depends on 100)

The formulation of claim 100, wherein the topical dosage form is a transdermal patch.
